The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF)
Tóm tắt
The randomized, double‐blind, double‐dummy, phase 3b
Từ khóa
Tài liệu tham khảo
Mesa R., 2015, Hydroxyurea treatment history and quality of life in patients with polycythemia vera: results from the MPN Landmark survey in the United States, Blood, 126, 10.1182/blood.V126.23.4077.4077
Najean Y., 1997, Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years, Blood, 90, 3370, 10.1182/blood.V90.9.3370
National Cancer Institute.Common Terminology Criteria for Adverse Events v3.0. Available at:http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed February 26 2016.
Scherber R., 2012, Conventional therapeutic options have limited impact on MPN symptoms: insights from a prospective analysis of the MPN‐SAF, Haematologica, 97
Squires M., 2013, The relationship between cytokine levels and symptoms in patients (pts) with myelofibrosis (MF) from COMFORT‐II, a phase 3 study of ruxolitinib (RUX) vs best available therapy (BAT), Blood, 122, 4070, 10.1182/blood.V122.21.4070.4070